Skip to main
ATRC

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure is well positioned to continue its double-digit sales growth driven by its innovative products in the fast-growing areas of cardiac ablation and LAA management. The company demonstrated strong sales and margin expansion in the 4Q25, and its earnings guidance for the upcoming year exceeds market expectations. Furthermore, AtriCure's potential for TAM expansion through clinical trials and adoption of its products as quality metrics in cardiac surgery adds to its long-term growth potential.

Bears say

AtriCure is facing competition in the LAAC market, particularly from Edwards Lifesciences, and while they have a strong position in the market due to their innovative product and proven efficacy and safety, the introduction of a competitor poses a potential risk to their market share and revenue growth. Additionally, slower than expected margin improvement and EBITDA growth, as well as weaker free cash flow, may further impact the company's financial performance. Despite these risks, we expect AtriCure to sustain at least low-teens overall revenue growth and reiterate our Buy rating.

AtriCure (ATRC) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Strong Buy based on their latest research and market trends.

According to 6 analysts, AtriCure (ATRC) has a Strong Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.